MedTrace Logo

Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma

NCT02786641 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 235

Last updated 2016-06-01

No results posted yet for this study

Summary

The investigators aim to evaluate the efficiency and toxicities of induction chemotherapy of docetaxel, cisplatin and xeloda in nomogram-predicted high risk locoregionally advanced nasopharyngeal carcinoma.

Conditions

  • Nasopharyngeal Carcinoma

Interventions

DRUG

Docetaxel

Docetaxel 65mg/m2 in induction chemotherapy

DRUG

Cisplatin 1

Cisplatin 75mg/m2 in induction chemotherapy

DRUG

Xeloda

Xeloda 2000mg/m2 D1-14 in induction chemotherapy

RADIATION

IMRT

IMRT for all patients

DRUG

Cisplatin 2

Cisplatin 100mg/m2 in concurrent chemotherapy

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2018-08-31
Completion
2021-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02786641 on ClinicalTrials.gov